Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD
Tofacitinib (Xeljanz) is now approved to treat adults with moderately to severely active ulcerative colitis. The oral Janus kinase inhibitor was previously approved for rheumatoid arthritis and psoriatic arthritis.
The ulcerative colitis indication was added based on data from three controlled trials. In two 8-week trials, twice-daily treatment with 10-mg tofacitinib was associated with remission rates of 17%–18%, versus 4%–8% with placebo. In the third trial, patients who had a clinical response to tofacitinib at 8 weeks and then took 5- to 10-mg twice daily had a 32%–41% remission rate by week 52, and those who were in remission by week 8 and continued treatment, 35%–47% had sustained steroid-free remission by week 52.
Common adverse events with tofacitinib include diarrhea, high lipid levels, and herpes zoster. Additionally, the drug's label carries a boxed warning about the potential for serious infections and lymphoma and other malignancies.
Comment
LINK(S):
FDA news release (Free)
Tofacitinib prescribing information (Free PDF)
Background: NEJM Journal Watch Gastroenterology coverage of tofacitinib phase III trials (Your NEJM Journal Watch registration required)